Evidence map›Paper›PMID 26105516›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).

Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto, Takako Doi, Kyuichiro Miyara, Hiroki Odagiri, Kaoru Kitamura, Keisuke Ariyoshi, Tempei Miyaji, Hiroto Ishiki and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
8.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. l-carnitine: Nutrition, pathology, and health benefits.Saudi journal of biological sciences · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Can l-carnitine reduce post-COVID-19 fatigue?Annals of medicine and surgery (2012) · 2022
    Review
  16. Coenzyme QNutrients · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. The Effect of CoQPsychology research and behavior management · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Satoru IwaseDepartment of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Takashi KawaguchiDepartment of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Daisuke YotsumotoDepartment of Breast Surgery, Sagara Hospital, 3-31 Matsubara-cho, Kagoshima City, Kagoshima, 892-0833, Japan.
Takako DoiKamakura Breast Cancer Center, Shonan Memorial Hospital, 2-2-60 Fueda, Kamakura-shi, Kanagawa, 248-0027, Japan.
Kyuichiro MiyaraMiyara Clinic, 2-3-1 Iso, Urasoe, Okinawa, 901-2132, Japan.
Hiroki OdagiriDepartment of Breast Surgery, Hirosaki National Hospital, 1 Tomino-cho, Hirosaki, Aomori, 036-8545, Japan.
Kaoru KitamuraNagumo Clinic Fukuoka, 2-8-1, Daimyo, Chuo-ku, Fukuoka, 810-0041, Japan.
Keisuke AriyoshiDepartment of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. k-ariyoshi@umin.ac.jp.
Tempei MiyajiJapanese Organization for Research and Treatment of Cancer (JORTC), 1-5-9-206, Yanaka, Taito-ku, Tokyo, 110-0001, Japan.
Hiroto IshikiDepartment of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Kenichi InoueKamakura Breast Cancer Center, Shonan Memorial Hospital, 2-2-60 Fueda, Kamakura-shi, Kanagawa, 248-0027, Japan.
Chizuko TsutsumiKamakura Breast Cancer Center, Shonan Memorial Hospital, 2-2-60 Fueda, Kamakura-shi, Kanagawa, 248-0027, Japan.
Yoshiaki SagaraDepartment of Breast Surgery, Sagara Hospital, 3-31 Matsubara-cho, Kagoshima City, Kagoshima, 892-0833, Japan.
Takuhiro YamaguchiJapanese Organization for Research and Treatment of Cancer (JORTC), 1-5-9-206, Yanaka, Taito-ku, Tokyo, 110-0001, Japan.
Shonan Kamakura General Hospital · JPJapanese Foundation For Cancer Research · JPNational Sagamihara Hospital · JPThe University of Tokyo · JPHirosaki National Hospital · JPOkinawa Prefecture · JPOno Clinic · JPTohoku University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancer patients in Japan.

methodsBreast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events.

resultsFifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed.

conclusionIP may control moderate-severe CRF in breast cancer patients.

trial registrationThe registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.

Indexed as

AdultAgedBreast NeoplasmsCarnitineFatigueFemaleHumansMiddle AgedQuality of LifeUbiquinoneCarnitinecoenzyme Q10UbiquinoneCancer-related fatigueChemotherapy-induced fatigueComplementary and alternative medicineQuality of lifeSupplement

Identifiers

PMID26105516
OpenAlexW828350488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.